Crossmark

Triple therapy of RAS inhibitors, dapagliflozin, and finerenone in diabetic kidney disease patients with nephrotic-range proteinuria: a real-world study

Crossref DOI link: https://doi.org/10.1038/s41598-025-27239-8

Published Online: 2025-12-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Gu, Chenjie

Li, Xinwei

Guo, Xianan

Zhou, Jingying

Kang, Le

Fang, Ming
Funding

Funding for this research was provided by:

National Natural Science Foundation of China (82100735)

Dalian Municipal Paramount Project Grant (2023DF001)
License Information

Text and Data Mining valid from 2025-12-08

Version of Record valid from 2025-12-08
More Information

Article History

Received: 4 April 2025

Accepted: 3 November 2025

First Online: 8 December 2025

Competing interests

: The authors declare no competing interests.

Document is current

Any future updates will be listed below